Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer
Pharmacy Times
JUNE 19, 2025
Perioperative treatment should be tailored today based on individual clinical and genomic features for patients with EGFR - and ALK -type [NSCLC],” concluded Biagio Ricciuti, MD, PhD, from the Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School.
Let's personalize your content